Clinical trial
Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure
NCT00030225 · Vital Therapies, Inc., Industry · Completed
Key facts
| NCT number | NCT00030225 |
|---|---|
| Title | Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure |
| Official title | Phase 2 Evaluation of the Vitagen Extracorporeal Liver Assist Device (ELAD) System in the Management of the Patients With Fulminant Hepatic Failure |
| Lead sponsor | Vital Therapies, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fulminant Hepatic Failure |
| Intervention type | Biological, Other |
| Interventions | ELAD, Standard of care (Control) |
| Enrollment | 19 |
| Start date | Jan 1, 2002 |
| Primary completion | Feb 1, 2003 |
| Completion | Feb 1, 2003 |
| First posted | Feb 12, 2002 |
| Last update posted | Jul 26, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: